Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells

Adachi,Makoto; Ijichi,Kei; Hasegawa,Yasuhisa; Nakamura,Hideaki; Ogawa,Tetsuya; Kanematsu,Nobutake

doi:10.3892/etm_00000017

Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells

Authors:
- Makoto Adachi
- Kei Ijichi
- Yasuhisa Hasegawa
- Hideaki Nakamura
- Tetsuya Ogawa
- Nobutake Kanematsu
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan. amakoto@yokohama-cu.ac.jp
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000017
Pages: 93-96

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to platinum-based chemotherapy frequently poses a serious problem in the treatment of head and neck squamous cell carcinoma. In this study, we isolated cisplatin-resistant cells from a head and neck squamous cell carcinoma cell line. The mismatch repair (MMR) system is known as one of the cisplatin-resistant mechanisms. When the expression levels of hMLH1 and hMSH2, a mismatch repair gene and its gene product, were analyzed, the hMLH1 mRNA and protein expression levels were significantly decreased in the cisplatin-resistant cell lines compared with a cisplatin-sensitive cell line. In addition, the microsatellite instability (MSI) phenotype was examined for the absence of MMR. Our data support the hypothesis that hMLH1 mRNA and protein expression levels are predictors of cisplatin sensitivity, but MSI was not involved in cisplatin resistance. The status of hMLH1 predicts the sensitivity of head and neck squamous cell carcinoma to platinum-based chemotherapy.

View Figures

View References

1.	Choong N and Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 58:32–53. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Wozniak K and Blasiak J: Recognition and repair of DNA-cisplatin adducts. Acta Biochim Pol. 49:583–596. 2002.PubMed/NCBI
3.	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD and Cullen KJ: Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol. 46:255–262. 2000. View Article : Google Scholar : PubMed/NCBI
5.	Papouli E, Cejka P and Jiricny J: Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 64:3391–3394. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Colella G, Marchini S, D’Incalci M, Brown R and Broggini M: Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer. 80:338–343. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA and Buller RE: Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 98:2199–2206. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Ishizaki K, Nishizawa K, Kato T, Kitao H, Han ZB, Hirayama J, Suzuki F, Cannon TF, Kamigaichi S, Tawarayama Y, Masukawa M, Shimazu T and Ikenaga M: Genetic changes induced in human cells in Space Shuttle experiment (STS-95). Aviat Space Environ Med. 72:794–798. 2001.PubMed/NCBI
9.	Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F and Perego P: Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets. 3:21–29. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Pani E, Stojic L, El-Shemerly M, Jiricny J and Ferrari S: Mismatch repair status and the response of human cells to cisplatin. Cell Cycle. 15:1796–1802. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Shimodaira H, Yoshioka-Yamashita A, Kolodner RD and Wang JY: Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA. 100:2420–2425. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavó E, di Pietro M, Marra G and Jiricny J: Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J. 22:2245–2254. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Stojic L, Brun R and Jiricny J: Mismatch repair and DNA damage signaling. DNA Repair. 3:1091–1101. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G and Berns EM: Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 31:2012006. View Article : Google Scholar
16.	Magnowska M, Surowiak P, Nowak-Markwitz E, Michalak M, Magnowski P, Rokita W, Kedzia H, Zabel M and Spaczyński M: Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients. Ginekol Pol. 79:826–834. 2008.PubMed/NCBI